Drug Database
BO

botulinum toxin type A (Coretox)

✓ Approved

Medytox · therapeutic agent

What is botulinum toxin type A?

botulinum toxin type A is a therapeutic agent developed by Medytox. It is approved for therapeutic indications via injectable (others).

Drug Profile

Brand NamesCoretox
CompanyMedytox
RouteInjectable (Others)
StatusApproved
Sources: ClinicalTrials.gov, Medytox

Therapeutic Indications

botulinum toxin type A is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Skin and subcutaneous tissue disordersSkin wrinkling✓ Approved
Musculoskeletal and connective tissue disordersMuscle spasmsPhase III

Related Research Articles

PubMedUgeskrift for laeger2026-10-22

[Newborn with neurofibromatosis type 1 and meningoencephalocele].

Weng Anna Tianjing AT, Lewis Anna Elisabet AE, Roslev Anne Cathrine AC

In this case report, a newborn with neurofibromatosis type 1 (NF1) and meningoencephalocele is presented. The foetus had inherited the same pathogenic defect in the NF1 gene as the father and was therefore closely monitored prenatally. The infant was born with a large frontonasal meningoencephalocele. This has not been described before and medical experience and knowledge is therefore sparse. In this case, early diagnostic imaging and scheduling of surgical intervention in collaboration with neuro- and plastic surgeons was performed.

PMID 42902764
Read full article →
PubMedFrontiers in psychology2026-10-22

Does second language decrease cyber deception? Cyber contextual organization of language and deception framework.

Zhang Chen C, Wang HongYu H

Cyber deception is common in online communication, yet whether using a foreign (second) language increases or decreases dishonest behavior remains debated. We propose the Cyber Contextual Organization of Language and Deception (CCOLD) framework, which integrates psychological dynamics (language), practical goals (lie type), and communication conventions (social norms) to predict cyber deception. In three online experiments, participants were randomly assigned to a native-language (Chinese) or foreign-language (English) condition and judged deception scenarios that varied in lie type (black lie vs. white lie in Experiment 1; white lie vs. truth in Experiment 2; black lie vs. truth in Experiment 3) and social norm (descriptive vs. subjective). Data were analyzed with linear mixed-effects models controlling for age, gender, language background, and self-reported English proficiency. The foreign-language effect was not uniform. Experiment 1 showed a language and lie interaction, such that foreign-language use increased the acceptability of black lies but not white lies. Experiments 2 and 3 showed three-way interactions: under subjective norms, foreign-language use reduced white-lie (Experiment 2) and black-lie (Experiment 3) willingness while increasing truth willingness, whereas language effects were not significant under descriptive norms. The effect of foreign language on cyber deception is conditional rather than fixed, jointly depending on lie type and social-norm type. The CCOLD framework accounts for these boundary conditions and offers implications for online ethical education and deception prevention.

PMID 42903162
Read full article →
PubMedSmall (Weinheim an der Bergstrasse, Germany)2026-10-22

Pre-Embedded CNTs Architecture Differentiates Carbon Functions for Kinetics Boosting in All-Solid-State Li-S Cathodes.

Zhu Zeyu Z, He Yufei Y, Li Qinyu Q, Peng Mingyue M et al.

All-solid-state lithium-sulfur batteries (ASSLSBs) are promising high-energy storage systems, yet their performance is severely limited by sluggish cathode kinetics due to the insulating nature of sulfur species and inefficient charge transport within the composite cathode. Herein, a functional-differentiation strategy via a pre-embedded carbon nanotubes (CNTs) framework is proposed to enhance the charge transport in sulfide-based ASSLSB cathodes. The design employs Li6PS5Cl (LPSC) as an ionic conductor, Ketjen black (KB) for sulfur hosting and short-range electron transfer, and pre-embedded CNTs as a long-range electronic conducting skeleton. Compared with conventional loading-type and bridging-type configurations, the framework-type CNTs-based cathode exhibits significantly improved charge transport and electrochemical performance. It delivers a discharge capacity of 1438 mAh g-1 at 1 C (2.5 mA cm-2), with 91.9% capacity retention after 400 cycles, and maintains 404 mAh g-1 under a high sulfur loading of 9 mg cm-2. Electrochemical analyses, local electrical mapping, and theoretical simulations reveal that the enhanced kinetics stem from a more homogeneous electronic network, which suppresses charge accumulation and facilitates Li+ transport. This work highlights that spatial reconstruction and functional differentiation of carbon components can effectively mitigate kinetic barriers in high-energy-density ASSLSBs.

PMID 42902932
Read full article →
PubMedTurkish journal of obstetrics and gynecology2026-10-22

Prenatal diagnosis of severe glutaric acidemia type II due to a novel homozygous ETFDH frameshift variant: Case report and literature review.

Kaplan Seda S, Polat Büşra Berfin BB, Melekoğlu Rauf R

Glutaric acidemia type II (GA2) is a rare autosomal recessive fatty acid oxidation disorder that can present prenatally with bilateral hyperechoic cystic kidneys. We report a 23-year-old gravida 2 woman who was referred at 18+2 weeks for suspected fetal renal anomalies, with a history of consanguinity and a prior unexplained neonatal death. Quantitative fluorescent polymerase chain reaction and microarray were normal; whole-exome sequencing identified a novel homozygous ETFDH frameshift variant (c.1200_1203del; p.His401GlnfsTer3). The parents were heterozygous, and the variant was classified as likely pathogenic. The family terminated the pregnancy after counseling. This case highlights both GA2 in the differential diagnosis of fetal renal anomalies and the value of prenatal exome sequencing for diagnosis and counseling.

PMID 42902630
Read full article →
PubMedPediatric endocrinology, diabetes, and metabolism2026-10-22

Mucopolysaccharidosis type IIIC diagnosed at the age of 12 years: Why was the disease diagnosed so late?

Lipiński Patryk P, Płoski Rafał R, Ługowska Agnieszka A

Mucopolysaccharidoses (MPS) are a group of inherited metabolic diseases associated with impaired lysosomal degradation of glycosaminoglycans. The aim of this manuscript is to report a case of a patient with mucopolysaccharidosis type IIIC (MPS IIIC) diagnosed at 12 years of age - to raise awareness among pediatricians, pediatric neurologists, and endocrinologists about the possible misdiagnosis. The patient was initially diagnosed with autism spectrum disorder and hyperactivity with normal motor development. During follow-up, psychomotor regression with moderate intellectual disability was observed. The patient was referred for further metabolic work-up only after the results of molecular analysis suggesting MPS IIIC. The final diagnosis was established based on clinical, biochemical, and molecular analyses.

PMID 42902708
Read full article →
PubMedPediatric endocrinology, diabetes, and metabolism2026-10-22

Refractory hypoparathyroidism in paediatric autoimmune polyglandular syndrome type 1: successful long-term use of teriparatide.

Perez Carolina C, Adarme Nicolas N, Hernandez Catalina C, Sarmiento Maria Paula MP

Autoimmune polyglandular syndrome type 1 (APS-1) is a rare monogenic disorder caused by pathogenic variants in the autoimmune regulator (AIRE) gene. It typically manifests in childhood with at least two features of the classic triad: chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency. We present the case of an 11-year-old girl from a consanguineous family, with severe hypocalcaemia and chronic oral candidiasis. Despite high-dose calcium and calcitriol therapy, she experienced recurrent symptomatic hypocalcaemia requiring multiple hospitalisations. Genetic testing confirmed homozygosity for the pathogenic AIRE variant c.967_979del, establishing the diagnosis of APS-1. Due to poor biochemical control, teriparatide (parathyroid hormone, PTH [1-34]) was initiated at 20 g twice daily, leading to rapid improvement in calcium-phosphate homeostasis, a 75% reduction in oral calcium requirements, and no further hospitalisations over a two-year period. The therapy was well tolerated with no adverse events. This is the first paediatric case reported in Colombia using recombinant PTH (1-34) for APS-1-related hypoparathyroidism, supporting its therapeutic role in refractory cases.

PMID 42902706
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about botulinum toxin type A